Immunocore (NASDAQ:IMCR) Stock Moved Down to Strong Sell by Zacks Research

Immunocore logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Zacks Research downgraded Immunocore from “hold” to “strong sell.” Despite that call, analysts overall had a “Moderate Buy” consensus and an average price target of $53.
  • Immunocore missed quarterly expectations, reporting a loss of $0.28 per share versus the $0.17 loss analysts expected, and revenue of $102.22 million versus an estimated $152.09 million.
  • HC Wainwright cut its price target from $100 to $80 but maintained a “buy” rating.
  • Five stocks we like better than Immunocore.

Immunocore (NASDAQ:IMCR - Get Free Report) was downgraded by investment analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a report issued on Monday, Zacks reports.

Other analysts also recently issued reports about the company. HC Wainwright reduced their target price on Immunocore from $100.00 to $80.00 and set a "buy" rating for the company in a research note on Tuesday. Wall Street Zen lowered Immunocore from a "buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunocore in a report on Monday, July 13th. Morgan Stanley set a $43.00 target price on shares of Immunocore in a report on Friday, August 7th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Immunocore in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $53.00.

Read Our Latest Stock Analysis on Immunocore

Immunocore Stock Performance

Shares of Immunocore stock opened at $32.38 on Monday. The company has a quick ratio of 4.44, a current ratio of 4.62 and a debt-to-equity ratio of 0.94. Immunocore has a twelve month low of $27.50 and a twelve month high of $40.71. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -49.81 and a beta of 0.82. The company's fifty day moving average is $31.46 and its 200 day moving average is $31.70.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). The company had revenue of $102.22 million during the quarter, compared to analyst estimates of $152.09 million. Immunocore had a negative net margin of 7.48% and a negative return on equity of 7.96%. Sell-side analysts forecast that Immunocore will post -0.04 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Several large investors have recently modified their holdings of IMCR. GAMMA Investing LLC lifted its stake in shares of Immunocore by 202.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company's stock valued at $61,000 after buying an additional 1,286 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Immunocore during the 3rd quarter valued at $72,000. Juncture Wealth Strategies LLC purchased a new stake in shares of Immunocore during the third quarter worth $207,000. denkapparat Operations GmbH purchased a new stake in shares of Immunocore during the second quarter worth $209,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Immunocore by 27.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company's stock worth $285,000 after acquiring an additional 1,975 shares during the period. Hedge funds and other institutional investors own 84.50% of the company's stock.

Key Immunocore News

Here are the key news stories impacting Immunocore this week:

  • Positive Sentiment: Shares crossed above their 200-day moving average, a potentially supportive technical signal, despite the earnings miss referenced in the report. Immunocore shares cross above 200-day moving average
  • Positive Sentiment: HC Wainwright maintained its Buy rating and an $80 price target—about 147% above the cited $32.38 share price—though the target was reduced from $100. HC Wainwright rating and price target
  • Neutral Sentiment: Immunocore presented at the Society for Immunotherapy of Cancer’s 2026 annual meeting; the available article is a slideshow and does not detail specific new clinical findings. SITC 2026 presentation slideshow
  • Negative Sentiment: HC Wainwright trimmed its 2027 EPS forecasts for Q1 ($0.17 from $0.18), Q2 ($0.26 from $0.29) and full-year 2027 ($1.34 from $1.36). It raised its Q4 estimate to $0.52 from $0.49, but the overall revisions were lower.
  • Negative Sentiment: The cut in HC Wainwright’s price target from $100 to $80 may weigh on sentiment, even with its Buy rating retained.

Immunocore Company Profile

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body's T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company's marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

See Also

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunocore Right Now?

Before you consider Immunocore, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.

While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines